Pancuronium: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
''Calculate based on ideal body weight'' | |||
*Intubation dose: bolus 0.06-0.1 mg/kg IV | |||
*Maintenance: 0.015-0.1 mg/kg IV q30-60min OR continuous infusion: 0.1 mg/kg/hr IV | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Neonates | |||
**Load: 0.02 mg/kg IV | |||
**Maintenance: 0.05-0.1 mg/kg IV q0.5-4hr PRN | |||
*>1mo | |||
**Load: 0.04-0.1 mg/kg IV | |||
**Maintenance: 0.015-0.1 mg/kg IV q30-60min OR continual infusion: 0.1 mg/kg/hr IV | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*Lactation: | *Lactation: Unknown | ||
*Renal Dosing | *Renal Dosing | ||
** | **CrCl 10-50 mL/min: Administer 50% normal dose | ||
** | **CrCl <10 mL/min: Do not use | ||
*Hepatic Dosing | *Hepatic Dosing: Use caution | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug or bromides | ||
*Caution if: | |||
**Following opioid, sedative or anesthetic agent (additive/synergistic effects) | |||
**Poor renal perfusion or severe renal disease | |||
**Preexisting tachycardia | |||
**>25% TBSA burns | |||
**HyperMg, hypoK, hypoCa (increased sensitivity) | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Anaphylaxis | |||
*Tachycardia, dose related | |||
*Bronchospasm | |||
*Hypotension | |||
===Common=== | ===Common=== | ||
*Tachycardia | |||
*Hypertension | |||
*Excessive salivation | |||
*Excessive sweating | |||
*Rash | |||
*Wheezing | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 2h | ||
*Metabolism: | *Metabolism: primarily none | ||
*Excretion: | *Excretion: Urinary | ||
*Mechanism of Action: | *Mechanism of Action: Non-depolarizing skeletal muscle relaxant; cholinergic receptor antagonist | ||
==See Also== | ==See Also== | ||
| Line 39: | Line 61: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Critical Care]] | |||
Latest revision as of 21:16, 23 September 2019
General
- Type: Neuromuscular blocker
- Dosage Forms:
- Common Trade Names:
Adult Dosing
Calculate based on ideal body weight
- Intubation dose: bolus 0.06-0.1 mg/kg IV
- Maintenance: 0.015-0.1 mg/kg IV q30-60min OR continuous infusion: 0.1 mg/kg/hr IV
Pediatric Dosing
- Neonates
- Load: 0.02 mg/kg IV
- Maintenance: 0.05-0.1 mg/kg IV q0.5-4hr PRN
- >1mo
- Load: 0.04-0.1 mg/kg IV
- Maintenance: 0.015-0.1 mg/kg IV q30-60min OR continual infusion: 0.1 mg/kg/hr IV
Special Populations
- Pregnancy Rating: C
- Lactation: Unknown
- Renal Dosing
- CrCl 10-50 mL/min: Administer 50% normal dose
- CrCl <10 mL/min: Do not use
- Hepatic Dosing: Use caution
Contraindications
- Allergy to class/drug or bromides
- Caution if:
- Following opioid, sedative or anesthetic agent (additive/synergistic effects)
- Poor renal perfusion or severe renal disease
- Preexisting tachycardia
- >25% TBSA burns
- HyperMg, hypoK, hypoCa (increased sensitivity)
Adverse Reactions
Serious
- Anaphylaxis
- Tachycardia, dose related
- Bronchospasm
- Hypotension
Common
- Tachycardia
- Hypertension
- Excessive salivation
- Excessive sweating
- Rash
- Wheezing
Pharmacology
- Half-life: 2h
- Metabolism: primarily none
- Excretion: Urinary
- Mechanism of Action: Non-depolarizing skeletal muscle relaxant; cholinergic receptor antagonist